science team2

Focus and Experience

Expertise that drives results

pro

Denis D Corin
CEO and Chairman

Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD:TPIV), a clinical stage immune -oncology company through 2014, He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.

pro

William Rosenstadt
General Counsel and Director

Mr. William Rosenstadt is a partner and a co-founder of Ortoli Rosenstadt LLP and head of the firm’s capital markets and securities practice and co-chair of the firm’s Asian practice. He has been practicing corporate and securities law since 1995. He represents entrepreneurs, public companies, hedge funds, private equity funds and other corporate entities on complex international and corporate transactions. He has represented public companies in the U.S., Europe and Asia. William is proud to be given the opportunity to help Q BioMed create value for its shareholders and bring life changing solutions to as many patients as possible.

DrRick

Dr. Rick Panicucci
Director and Advisor Pharmaceutical Development

Rick is currently the SVP of CMC at QED Therapeutics, Origin Bioscences and Calcilytix Therapeutics all BridgeBio Companies. Prior to joining BridgeBio, Rick served as VP of Pharmaceutical Development Services at WuXi STA, where he provided scientific leadership in formulation development and GMP manufacturing. From 2004 to 2015, Rick was Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis. His responsibilities included all small molecule therapeutics across the Novartis portfolio. He also lead and developed novel drug delivery technologies for small molecules and large molecules. Rick has also led R&D groups at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. He received a Ph.D. in Chemistry from the University of Toronto and did a Post-Doctoral Fellowship at UCSB.

pro

David Laskow-Pooley
VP Product Developmen

Mr. Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. He has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life technologies, OSI, Bilcare and Surface Therapeutics.

pro

Ari Jatwes
Business Development Analyst

Mr. Ari Jatwes is an analyst and a banker, with over twenty years of experience. He began his career in a large accounting firm, progressing to a reputable investment bank, where he gained his experience in mergers and acquisitions. Over the last decade Mr. Jatwes interest and focus has been in the biotech and pharma sector, which included trading biotech stocks from start up to late stage biotech companies, advising management and raising capital for their needs. He has played a role in several successful contracts and transactions in the healthcare space – with emphasis on the life sciences and immunotherapy. Mr. Jatwes holds two Master degrees and a Bachelor Degree from the University of South Africa and the University of Natal

Robert Derham

Robert Derham
VP Orphan Products

Robert Derham has focused the majority of his career working with rare diseases and orphan products. For the past seven years he has focused on driving corporate change within medium and large pharmaceutical companies to transition their corporate strategy to an orphan drug development approach. In addition to driving corporate change, he conducted business development for companies looking for partnering, licensing or acquisition opportunities in the orphan drug space. Prior to that, he worked for Mondobiotech, Novartis, Syngenta Biopharma and Alexis Biopharma, always focused on orphan indications and corporate development. Robert is also the founder of CheckOrphan, a comprehensive media and information source for all news, videos, clinical trials, research, treatments and more about rare diseases and orphan products. He also has degrees in medical immunology and biochemistry and thoroughly enjoys diving into the science and research of the rare diseases, with which he is working.

RIPKA headshot

Amy Ripka
Advisor Medicinal Chemistry

Dr. Amy Ripka has 19 years of drug discovery expertise spanning big pharma to CRO leadership positions. At Bristol-Myers Squibb, Amy was part of the teams that discovered and developed Asunaprevir and Daclatasvir, for the treatment of Hepatitis C. Later as Head of Chemistry at EnVivo/FORUM, Amy led the discovery and development of their PDE10 inhibitor to the clinic. Amy has cross-functional experience leading teams at several notable Boston biotechs and has served on Executive Teams at two CROs, SAI Life Sciences and WuXiAppTec. There her role was to advise and guide clients through preclinical drug discovery to IND planning and engagement of institutional investors/foundations. Recently, Amy founded Lucy Therapeutics, a Boston biotech focused on improving mitochondrial respiration for treatment of Rett Syndrome. Amy chaired the Medicinal Chemistry Gordon Conference in 2012 and has been on the ACS MEDI Executive Committee for 6 years. She has served on SABs of national/international meetings and is currently a SAB member of Rheostat Therapeutics.

 

ADVISORY BOARD

Dr. Scott Brunder

Wombat Capital Advisors
Medical Devices

Mary Jan Rafii

Wombat Capital Advisors Opthalmology

Dr. Helga Grupe

Wombat Capital Advisors
Oncology

Dr. Jose de Chastonay

Wombat Capital Advisors
Contract Services

Dr. Susan Quaggin

CSO, Mannin Research

George Nikopoulos

CEO, Mannin Research